Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01384708 · ClinicalTrials.gov registry record · Early Phase 1
Evaluation of a Miniaturized Microscope Device for the Detection of Esophageal Squamous Cell Cancer
A Early Phase 1 study of Squamous Cell Cancer, sponsored by Anandasabapathy, Sharmila, M.D..
- Completed
- Registry status
- Early Phase 1
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT01384708: Completed Early Phase 1 study of Squamous Cell Cancer, sponsored by Anandasabapathy, Sharmila, M.D..
NCT01384708 is a Early Phase 1 study of Squamous Cell Cancer that has completed, run by Anandasabapathy, Sharmila, M.D.. The registered enrollment target is 70 participants, below the 102-participant average among 3 other Squamous Cell Cancer trials with a reported enrollment target (31% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01384708, a Early Phase 1 study of Squamous Cell Cancer, has completed, sponsored by Anandasabapathy, Sharmila, M.D..
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall objective of this study is to determine whether high-resolution imaging of the esophagus during routine diagnostic upper endoscopy can assist clinicians in detecting and discriminating dysplastic (precancerous) areas. This high-resolution microendoscope (HRME) was developed by our collaborators at Rice University and provides \> 1000x magnified images of the esophageal mucosa. The purpose of this study is to determine whether this device can be used to enhance the diagnostic accuracy of routine endoscopic screening for squamous cell cancer of the esophagus.
Conditions Studied
Interventions
- DRUG proflavine
Study Locations (1)
New York
- Mount Sinai Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2010-08 |
| Est. Completion | 2013-10 |
| Phase | Early Phase 1 |
What the finished NCT01384708 record still lists
NCT01384708 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 102-participant average among 3 other Squamous Cell Cancer trials with a reported enrollment target (31% lower).
The record links to 1 condition, with Squamous Cell Cancer appearing as the primary indexed condition, and to 1 intervention - of which proflavine is the first listed.
NCT01384708 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT01384708 about?
NCT01384708 is a clinical study titled "Evaluation of a Miniaturized Microscope Device for the Detection of Esophageal Squamous Cell Cancer". The overall objective of this study is to determine whether high-resolution imaging of the esophagus during routine diagnostic upper endoscopy can assist clinicians in detecting and discriminating dysplastic (precancerous) areas. This high-resolution microendoscope (HRME) was developed by our collab...
What is the current status of trial NCT01384708?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 70 participants. The study started on 2010-08. Estimated completion is 2013-10.
What conditions does trial NCT01384708 study?
This clinical trial studies the following conditions: Squamous Cell Cancer.
What interventions are being tested in trial NCT01384708?
The interventions under investigation include: proflavine (DRUG).
Who is sponsoring clinical trial NCT01384708?
This trial is sponsored by Anandasabapathy, Sharmila, M.D., which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01384708 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Squamous Cell Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
-
R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors
RECRUITING · Phase 1
-
Role of Immune Activation in Response of Head and Neck Squamous Cell Carcinoma to Therapy
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia